InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions... Show more
a developer of minimally-invasive aesthetic medical products
Industry MedicalNursingServices
A.I.dvisor indicates that over the last year, INMD has been loosely correlated with UTMD. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if INMD jumps, then UTMD could also see price increases.
| Ticker / NAME | Correlation To INMD | 1D Price Change % | ||
|---|---|---|---|---|
| INMD | 100% | +0.49% | ||
| UTMD - INMD | 47% Loosely correlated | -0.76% | ||
| RVTY - INMD | 45% Loosely correlated | +0.29% | ||
| CRL - INMD | 45% Loosely correlated | -0.54% | ||
| MTD - INMD | 45% Loosely correlated | -0.49% | ||
| AZTA - INMD | 45% Loosely correlated | -0.53% | ||
More | ||||
| Ticker / NAME | Correlation To INMD | 1D Price Change % |
|---|---|---|
| INMD | 100% | +0.49% |
| Health Services category (241 stocks) | 1% Poorly correlated | -0.69% |
| Medical/Nursing Services category (140 stocks) | 1% Poorly correlated | -0.41% |
The RSI Oscillator for INMD moved out of oversold territory on September 25, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 24 of the 33 cases the stock moved higher. This puts the odds of a move higher at 73%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where INMD advanced for three days, in 177 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
INMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INMD as a result. In 75 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
INMD moved below its 50-day moving average on September 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for INMD crossed bearishly below the 50-day moving average on August 31, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
The Aroon Indicator for INMD entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. INMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 63 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.304) is normal, around the industry mean (10.865). P/E Ratio (11.785) is within average values for comparable stocks, (98.603). Projected Growth (PEG Ratio) (0.834) is also within normal values, averaging (11.050). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.452) is also within normal values, averaging (39.828).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.